Avellino Labs to Pioneer the Development of Cornea Gene
Therapy
MENLO PARK, California,
April 30, 2016 /PRNewswire/
-- Avellino Labs, developer of the first and only commercially
available genetic test for corneal health, today announced that
Tara Moore, PhD has joined the
company as R&D Director overseeing all of the company's global
research programs, with special emphasis on gene therapy.
Logo: http://photos.prnewswire.com/prnh/20130514/SF12152LOGO
To view the Avellino Labs press kit for ASCRS 2016, please
visit:
http://health-event-news.vporoom.com/AvellinoLabs-ASCRS
Professor Moore is currently the Director of the Biomedical
Research Institute as well as Group Leader of Vision Science
Research in the School of Biomedical Science at Ulster
University. A Harvard graduate
with a wealth of experience in working with universities and
laboratories across the UK, Europe
and the USA, Tara has made
tremendous advances in progressing novel diagnoses and treatments
for blinding eye diseases. The focus of her research is the
optimization of gene silencing and gene editing to target the
causative mutation in a personalized medicine approach to the
treatment or prevention of corneal dystrophy. Avellino Labs
welcomes Tara's unique expertise in molecular biology combined with
two decades of ophthalmology research and use of novel preclinical
human models to advance the translation of new therapies to
patients. She has published over 100 peer reviewed
international research articles, numerous book chapters, two books
and manages a team of students and scientists in her university
laboratory.
"I am excited and delighted to join Avellino Labs at this time
of incredible growth and discovery. Working with the team
already assembled at Avellino Labs, we plan to revolutionize the
practice of medicine in ophthalmology by developing novel tools for
the detection, treatment, and possible cure for anterior eye
disease using state-of-the-art technology," commented Professor
Moore.
"We are thrilled to have Professor Moore join our efforts. She
brings a wealth of experience, knowledge, and passion to our
company," stated Avellino Labs Chairman and Founder, Gene Lee. "She will be a tremendous asset
in achieving our goal to deliver personalized medicine to doctors
and patients."
About Avellino Labs
Avellino Labs has developed
the first and only commercially available genetic testing system
for corneal health. Currently, the Universal Test detects the
TGFBI mutations that are responsible for Granular Corneal Dystrophy
type 1 (GCD1), Granular Corneal Dystrophy type 2 (GCD2), Lattice
Corneal Dystrophy type 1 (LCD1), Reis-Bucklers Corneal Dystrophy
(RBCD), and Thiel Behnke Corneal Dystrophy (TBCD).
Based on the test's results, patients and their physician can make
an informed decision when considering vision correction surgery.
Avellino Labs' proprietary genetic
diagnostics system provides fast, safe and affordable DNA
analysis. The company continues to develop new
applications for genetic analysis of various ocular conditions,
with the ultimate goal of gene therapy for eye disease.
To learn more please visit http://www.avellinolab.com/us/.
Media Contact:
Paula Hook, Marketing Communications
Director
+1 972.517.1784 / (cell) +1 214.356.4427
paula.hook@avellinolab.com